[Effects on the bone metabolism of long-term treatment with antivitamins K1].
Oral anticoagulants (OC) prevent the activation by carboxylation of coagulation proteins. However this action also affects osteocalcin, or bone Gla-protein, a parameter of bone remodelling. Phosphorus and calcium metabolism, osteocalcin levels and bone mineral content were studied in twelve men aged under 60, and who had been taking OC for more than a year, in comparison with a paired group of nine controls with the same cardiovascular pathology but not taking anticoagulants. Osteocalcin levels were lower in the OC group (3.44 ng/ml) than in the control group (5.88 ng/ml) (p = 0.01). There was no significant difference in other phosphorus/calcium balance parameters nor in bone density between the two groups. No evidence was found of any osteopathy in the OC group, but the decrease in serum osteocalcin could result either from inhibition of its secretion or of its carboxylation, or from an action on the osteoblast.
Van der Linden
T
T
Service de Cardiologie et Médecine interne, Centre Hospitalier St-Philibert, Lomme.
Houvenagel
E
E
Graux
P
P
Leloire
O
O
Forzy
G
G
Cabaret
P
P
Tison
F
F
Marchandise
X
X
Dutoit
A
A
Vincent
G
G
D000925:Anticoagulants / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D011446:Prospective Studies; D013997:Time Factors; D010837:Vitamin K 1 / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D015675:Osteocalcin; D010837:Vitamin K 1
Retentissement sur le métabolisme osseux des traitements au long cours par les antivitamines K1.